The clinical stakes are laid bare in the opening case. Mr. Warren, hospitalized with bacteremia caused by resistant gram-negative bacteria, repeatedly requested discharge because standard withdrawal treatments were not controlling his symptoms. His care team started with methadone, his preferred medication for opioid use disorder, along with clonidine and symptomatic adjuncts. When those measures failed and he again moved to leave, the team turned to high doses of intravenous hydromorphone, delivered through a patient-controlled analgesia pump that allowed smaller, more frequent doses with lockout periods. The objective signs of withdrawal, including elevated heart rate, dilated pupils, yawning, tremors, goosebumps, vomiting, diarrhea, and sweating, all ceased. What remained were cravings, which the author identifies as a cornerstone symptom of withdrawal and the predominant driver of the patient’s urge to leave.

The central argument of the viewpoint is that opioid withdrawal, including uncontrolled cravings, should be treated as an acute, life-threatening illness requiring prompt management, just as sepsis or diabetic ketoacidosis would be. Rose contends that the historical framing of withdrawal as uncomfortable but benign has bred complacency. In reality, untreated or undertreated withdrawal is a common cause of premature hospital discharge and a rapid return to fentanyl use, which acutely raises mortality both through overdose and through complications of foregone medical care. Avoidance of withdrawal, he notes, is also a major reason patients with opioid use disorder continue to use opioids in the first place.

Fentanyl has magnified these dangers. As the dominant non-prescribed opioid across the United States, it carries a markedly higher overdose risk than heroin or prescription opioids. Its brief duration of action increases injection frequency, compounding risks of infectious complications such as endocarditis and viral hepatitis. Its potency also raises patient tolerance, and its accumulation in tissues prolongs withdrawal, often making traditional methadone titrations unbearable and increasing the risk of precipitated withdrawal when buprenorphine is initiated. Clinicians are therefore increasingly confronting hospitalized patients with severe illness whose withdrawal and cravings cannot be controlled by conventional protocols alone.

The pharmacological rationale for intravenous therapy follows established practice in other acute conditions. For pathologies ranging from sepsis to heart failure to diabetic ketoacidosis, intravenous medications are initially required to achieve faster clinical improvement and offer superior titratability. The same logic applies to other withdrawal syndromes, such as alcohol withdrawal, and to opioid use for acute pain. Intravenous opioids produce a rapid rise in drug concentrations that facilitates swift symptomatic relief, while their short half-lives reduce the risk of accumulation. Patient-controlled analgesia pumps, which require active patient participation and enforce lockout intervals, can safely deliver the large morphine-equivalent doses demanded by patients with especially high fentanyl-driven tolerances while granting them a measure of autonomy over their own treatment.

Short-acting opioids, whether intravenous or oral, already have a recognized adjunctive role in the literature. They can fill residual opioid agonism deficits during methadone titrations. During buprenorphine initiation, they can be used for symptom control while fentanyl clears from the body, alongside buprenorphine during low-dose initiations, or to treat precipitated withdrawal if it occurs. This adjunctive use is described as an increasingly accepted harm reduction practice. What remains undefined, and what the viewpoint seeks to address, is the specific role of the intravenous route, whose absence from formal guidance has produced uncertain and inconsistent use across hospitals.

A crucial element of the argument is the assessment of risk. Clinicians rightly worry that the association between receiving opioids and relief from distress or cravings could reinforce, rather than reverse, the learned behavior that opioids are a solution to stressors. Faster time to peak effect, a hallmark of intravenous administration, is known to increase this reinforcing potential. However, Rose argues that for hospitalized patients with severe opioid use disorder, fentanyl use, and uncontrolled withdrawal, the risk of worsening the disorder is low while the benefit of controlling symptoms, thereby facilitating ongoing medical care including addiction treatment, is high. As time and treatment suppress withdrawal and cravings and the acute medical illness improves, the risk-benefit calculus reverses, and short-acting opioids should be discontinued.

The viewpoint is emphatic that intravenous opioids are never a substitute for evidence-based treatment. Medications for opioid use disorder should be recommended to all patients and serve as the backbone of withdrawal management, with buprenorphine or methadone identified as the most effective treatments even for patients uninterested in continuing them after discharge. Alpha-2 agonists such as clonidine or lofexidine should be first-line adjunctive therapies unless contraindicated. Symptomatic treatment with anxiolytics like hydroxyzine, antiemetics like ondansetron, antispasmodics like dicyclomine, antidiarrheals like loperamide, and non-opioid pain medications such as NSAIDs should also be deployed as needed. Short-acting opioids enter the picture only for patients with residual symptoms despite these measures, or in rare instances where patients decline buprenorphine and methadone entirely and the medications are used to facilitate hospital-based care.

Route selection and expectation setting form the practical core of the proposed guidance. Because the reinforcing risk of rapid-onset opioids is amplified with prolonged use, oral opioids should be prioritized once initial withdrawal symptoms have improved and effective doses have been identified. This transition also smooths drug exposures, offering more consistent symptom control throughout the day. Plans to move from intravenous to oral therapy and eventually to discontinue short-acting opioids altogether should be established with patients early. Once patients reach therapeutic buprenorphine doses, typically 16 to 24 milligrams daily, short-acting opioids should no longer be required. Methadone initiation is typically slower, and patients should understand that short-acting opioids will be tapered as methadone is increased, a process that growing evidence suggests can be expedited through more rapid titration schedules.

The case concludes with hard-won but partial success. Mr. Warren’s symptoms improved on the patient-controlled pump, which was transitioned to oral therapy over subsequent days. As methadone was uptitrated, the short-acting opioids were tapered and eventually discontinued. He remained hospitalized for fourteen days of intravenous antibiotics, his first full treatment course in years. On the eve of transfer to rehabilitation, he again packed his bag and requested discharge, and this time no argument could dissuade him. He left with naloxone, a month’s supply of his medications, and a handshake. His infection was cured and he was alive, but not yet ready for recovery. That outcome, the viewpoint suggests, is precisely the point: intravenous opioids did not cure addiction, but they kept a critically ill patient in the hospital long enough to cure the infection that would otherwise have killed him, and they bought time that conventional withdrawal management alone could not.

Subject of Research: Use of intravenous opioids to manage opioid withdrawal in hospitalized patients with opioid use disorder

Article Title: The Role of IV Opioids for Opioid Withdrawal in Hospitalized Patients

Article References: Rose, M. R. (2026). The Role of IV Opioids for Opioid Withdrawal in Hospitalized Patients. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10856-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10856-y

Keywords: opioid withdrawal, intravenous opioids, opioid use disorder, fentanyl, methadone, buprenorphine, hospitalized patients, harm reduction, patient-controlled analgesia, medications for opioid use disorder, withdrawal management, internal medicine

The three-day rule is a provision of federal regulation that permits practitioners who are not affiliated with an OTP to administer methadone to a patient for the purpose of relieving acute withdrawal symptoms while arranging referral to a licensed program. The allowance is capped at three days, and it cannot be renewed within the same month. In practice, it has historically been used sparingly, because clinicians have worried about safety and because the short window seems ill-suited to overcoming the administrative delays that often accompany OTP enrollment. The new research, published in the journal Addiction Science & Clinical Practice, offers a detailed real-world test of the approach as implemented at the San Francisco General Hospital Bridge Clinic, a low-threshold service designed to meet patients where they are.

The study team, led by Sarah Rosenwohl-Mack of UCSF’s Department of Family and Community Medicine, conducted a retrospective case series covering every patient who initiated methadone under the three-day rule at the Bridge Clinic between June 2024 and July 2025. The setting is notable for an unusual piece of geography: the hospital also houses an opioid treatment program in the same building. When that program could not complete an intake, for example because a patient arrived outside scheduled intake hours or the program was at capacity, staff could refer the person down to the Bridge Clinic, where a dose of methadone could be started immediately under the three-day provision. This bidirectional referral pathway became the study’s central variable.

The researchers tracked two primary outcomes. The first was linkage to an OTP within seven days of receiving the initial Bridge Clinic dose, a window that extends beyond the three-day medication allowance and therefore captures whether the bridge actually carried patients to permanent care. The second was retention in OTP treatment at 30 days, a marker of early stability that addiction medicine researchers view as a meaningful predictor of longer-term benefit. Because methadone carries its own risks, particularly when combined with other sedatives, the team also built in a safety monitoring framework that reviewed urine drug screens, emergency department visits, hospitalizations within seven days, and Medical Examiner overdose reports.

The results are striking for a population that conventional systems routinely lose. Among 166 unique patients who received at least one dose of three-day methadone at the Bridge Clinic, 63 percent, or 104 individuals, successfully linked to an opioid treatment program within seven days. Of those who linked, 62 percent, or 64 patients, were still retained in treatment at the 30-day mark. In a field where attrition between first contact and enrollment has long been considered one of the most stubborn leaks in the continuum of care, the finding suggests that a short bridge of medication can hold a substantial fraction of patients long enough for the formal system to catch up with them.

The most consequential finding, however, concerned the direction of the referral. Using multivariable logistic regression to adjust for other factors, the researchers found that patients who arrived at the Bridge Clinic by referral from the co-located OTP had 3.1-fold higher odds of remaining in treatment at 30 days compared with patients who came through other routes. The interpretation is not that the referral itself dispensed a pharmacological benefit, but that the pathway reflects a coordinated system in which the OTP and the Bridge Clinic function as two doors into the same building of care. A patient handed off from the OTP arrives with an established clinical relationship, a documented treatment plan, and a clear route back, whereas a patient walking in cold must navigate enrollment largely on their own after the three-day window closes.

On the safety side, the record was clean in ways that will reassure clinicians who have hesitated to use the three-day rule. The study identified no methadone-related emergency department visits, no hospitalizations, and no deaths within 30 days of receiving methadone at the Bridge Clinic. The urine drug screen review, designed to flag unexpected results such as methadone positivity in patients not prescribed it or the absence of non-prescribed opioids suggesting diversion, surfaced only one notable case: a single patient who, on closer chart review, turned out to have already been enrolled in methadone treatment elsewhere before receiving a dose at the Bridge Clinic. That finding points to a practical quality-control challenge, ensuring that bridge dosing does not duplicate existing treatment, but it does not undermine the overall safety signal.

The technical logic of the intervention deserves attention. Methadone is a long-acting full mu-opioid receptor agonist with a half-life that supports once-daily dosing, which is precisely why it smooths the cycle of withdrawal and craving that drives much of the daily chaos in untreated opioid use disorder. When a patient presents in withdrawal, the clinical task is to provide enough of the medication to relieve symptoms without accumulating toxicity, which is why Bridge Clinic protocols begin with conservative doses and titrate carefully. The three-day rule fits neatly into this pharmacology: three days of supervised dosing is enough to stabilize a patient physiologically and to interrupt the withdrawal-driven urgency that otherwise pushes people back to fentanyl and other illicit opioids, while the referral machinery works in parallel to secure a permanent slot at an OTP.

The San Francisco team acknowledges intellectual debts in the paper, crediting the Faster Paths Emergency Opioid Withdrawal Protocol at Boston Medical Center, whose published approach informed the local protocol. That lineage matters because it illustrates how low-threshold models are spreading through a kind of open-source clinical adaptation, with programs borrowing and refining each other’s protocols rather than waiting for multi-year trials. The study itself was deemed exempt by the UCSF Institutional Review Board and used retrospectively collected anonymized data, a design that trades the rigor of randomization for the realism of observing how an intervention performs inside the ordinary friction of a public hospital.

The implications reach well beyond one clinic. Opioid treatment programs remain the only legal channel for methadone maintenance in the United States, and their geographic maldistribution means that many counties have no OTP at all. The three-day rule cannot substitute for structural reform, but the study demonstrates that when a low-threshold bridge service and a licensed OTP are deliberately networked, the rule becomes a functional handoff mechanism rather than a rarely used legal footnote. The 3.1-fold retention advantage associated with OTP referral suggests that the return on investment lies in building those connections, ensuring that every bridge dose is paired with a warm pathway back into licensed care. For a lethal epidemic that has proven resistant to conventional outreach, the message is deceptively simple: meet people in withdrawal with medication the same day, and engineer the system so that the door they entered stays open behind them.

Subject of Research: Three-day methadone bridging at a low-threshold clinic to improve linkage and retention in opioid treatment programs

Article Title: Implementing three-day methadone in a low-threshold Bridge Clinic: impact of OTP referral pathways on treatment retention

Article References: Rosenwohl-Mack, S., Suen, L. W., Hart, R., Steiger, S., Hom, J. K., & Snyder, H. (2026). Implementing three-day methadone in a low-threshold Bridge Clinic: impact of OTP referral pathways on treatment retention. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00725-8

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00725-8

Keywords: methadone, opioid use disorder, opioid treatment program, Bridge Clinic, three-day rule, treatment retention, harm reduction, San Francisco General Hospital, low-threshold care, withdrawal management, addiction medicine, medication for opioid use disorder

The clinical problem behind the study is rooted in the transformation of the illicit drug supply. In British Columbia and across much of North America, unregulated fentanyl has largely displaced heroin, and most people entering hospital with opioid use disorder are now fentanyl-dependent. Traditional induction onto opioid agonist treatment, which typically relies on methadone or buprenorphine started at low doses, was designed around the pharmacology of shorter-acting opioids. Because fentanyl is extraordinarily potent, highly lipophilic, and accumulates in fat stores from which it slowly re-releases, patients dependent on it can experience severe, protracted withdrawal even when standard buprenorphine initiation protocols are followed. Precipitated withdrawal, in which the partial agonist buprenorphine abruptly displaces fentanyl from opioid receptors and triggers sudden, intense withdrawal symptoms, is a well-recognized failure mode that can cement a patient’s distrust of hospital-based care.

SIFI approaches the problem from the opposite direction. Rather than starting with a medication designed to displace fentanyl, clinicians use fentanyl itself, delivered intravenously in controlled, repeated doses, to suppress withdrawal symptoms until the patient is physiologically stable enough to transition onto a longer-acting opioid agonist such as slow-release oral morphine or methadone. The protocol is guided by structured monitoring instruments, including the Clinical Opioid Withdrawal Scale, which quantifies withdrawal severity, and the Pasero Opioid-Induced Sedation Scale, which grades sedation depth. Nurses assess respiratory rate and sedation before each dose, and administration is inhibited when clinical signs indicate accumulating opioid effect. In principle, this titration logic mirrors how any hospital manages pain with intravenous opioids, but here the goal is not analgesia alone; it is a deliberate, supervised pharmacological bridge from the chaotic unregulated supply to regulated, prescribed therapy.

The research team, drawn from Vancouver General Hospital’s Complex Pain and Addiction Service and collaborating institutions including the University of British Columbia and the BC Centre for Excellence in HIV/AIDS, conducted a retrospective chart review of patients prescribed the SIFI protocol at their institution. The investigators registered the study on ClinicalTrials.gov before data collection and examined a battery of outcomes: adverse events during induction, self-directed discharges during or after the protocol, whether the primary reason for hospital admission was ultimately addressed, transition onto opioid agonist treatment, emergency department visits or readmissions within thirty days of discharge, and the dosing characteristics of the induction itself. The cohort comprised seventeen patient encounters, involving sixteen individuals, one of whom underwent SIFI during two separate admissions.

The safety findings are the study’s most reassuring result. Across all encounters, SIFI produced transient sedation in three patients, none of whom required resuscitation, and no serious adverse events were recorded. This matters because fentanyl’s potency and its tendency to accumulate in tissue raise legitimate concerns about respiratory depression when the drug is administered repeatedly. The structured sedation scoring embedded in the protocol appears to have caught accumulating opioid effect before it reached dangerous territory. The authors caution, appropriately, that the cohort is small and the design retrospective, so the safety signal must be confirmed in larger, prospective studies. Nonetheless, in a population where untreated withdrawal itself carries serious risks, including dehydration, cardiac strain, and profound distress that drives patients back to the toxic unregulated supply, even preliminary evidence of tolerability is consequential.

The efficacy signals, while more mixed, are striking in places. Compared with admissions in the three months before SIFI was used, patients who received the induction stayed dramatically longer in hospital before leaving against medical advice. Mean time in hospital before self-directed discharge rose from 0.2 days to 9 days for the entire cohort, and among patients who did not leave against advice, the average reached 49.2 days. In practical terms, patients who previously walked out within hours of admission remained long enough for clinical teams to address the infections, wounds, or other conditions that brought them in. Most patients had their primary reason for admission addressed, six patients were established on opioid agonist treatment at discharge, and the cohort showed lower readmission rates in the month following admission compared with their historical pattern.

The results are not uniformly favorable. The proportion of admissions ending in self-directed discharge actually increased after SIFI, from 51 percent of encounters in the pre-induction period to 65 percent afterward. The authors interpret this pattern cautiously, noting that the comparison periods and denominators differ and that patients selected for SIFI may represent a particularly high-acuity group whose risk of leaving against advice is extreme. Even so, the finding underscores a central tension in addiction hospital medicine: an intervention can extend stays and improve clinical completion rates for many patients while the overall rate of early departure remains stubbornly high. Withdrawal management during hospitalization, however well executed, competes with the pull of the unregulated supply, the discomfort of institutional settings, and the cumulative distrust many patients carry from prior experiences with the health system.

Why does an intravenous fentanyl induction resonate so strongly with patients who have resisted other forms of treatment? The answer likely lies in the pharmacology of tolerance. A person using unregulated fentanyl daily may require doses of buprenorphine or methadone far above conventional starting amounts to feel any effect, and standard low-dose initiations can leave them in days of untreated withdrawal. By titrating intravenous fentanyl to symptom control, SIFI effectively replicates the doses patients have been self-administering, then transitions them to a regulated, longer-acting alternative once stability is achieved. Slow-release oral morphine, which is used in some Canadian programs for patients who do not respond to first-line agonists, features in the protocol’s transition pathway. The strategy acknowledges a harm-reduction principle that has gained traction in Canadian medicine: for some patients with severe fentanyl use disorder, the pragmatic goal is a regulated opioid supply rather than immediate abstinence.

Broader context sharpens the significance of these findings. British Columbia declared a public health emergency over illicit drug toxicity in 2016, and deaths from unregulated fentanyl have remained catastrophically high since. Hospital admissions represent one of the few guaranteed contact points between this population and the health system, yet they are too often wasted opportunities punctuated by abrupt, withdrawal-driven departures. Interventions that lengthen hospital stays, address the presenting medical problem, and link patients to ongoing treatment could bend mortality curves that have resisted conventional approaches. The study was funded through donor support to the VGH and UBC Hospital Foundation, received ethics approval from the University of British Columbia Clinical Research Ethics Board, and was conducted in accordance with the Declaration of Helsinki, with informed consent obtained from participants.

The path forward will require the studies this retrospective review cannot replace: prospective trials with larger cohorts, comparator arms testing SIFI against standard buprenorphine or methadone inductions, and careful attention to dosing parameters that the chart review only partially captures. Questions about optimal titration ceilings, the ideal timing and target of transition to long-acting agonists, and generalizability beyond a single quaternary hospital with an established addiction consult service all remain open. Still, the Vancouver team’s data sketch a plausible answer to one of addiction medicine’s most frustrating failure modes. For patients in the grip of fentanyl dependence, arriving at a hospital has too often meant arriving at a doorway they quickly exit. A protocol that suppresses withdrawal with the drug their bodies know, monitors sedation with validated scales, and builds a bridge to regulated treatment turned hours-long stays into stays averaging nine days, addressed the medical problems that brought patients through the door, and left a meaningful fraction on therapy at discharge. In a crisis defined by toxic supply and revolving-door admissions, that combination of safety and engagement is a result worth rigorous pursuit.

Subject of Research: Symptom-inhibited fentanyl induction as a hospital-based opioid agonist therapy initiation protocol for patients with fentanyl-dependent opioid use disorder

Article Title: Symptom-inhibited fentanyl induction (SIFI) for hospitalized patients with opioid use disorder: a retrospective chart review

Article References: Li, V. W., Wong, J. S. H., Kim, J. J., Machado, J., Hawamdeh, A. A., Schneiderman, H., Nalliah, S., Harris, M., Montaner, J. S. G., Ignaszewski, M. J., & Azar, P. (2026). Symptom-inhibited fentanyl induction (SIFI) for hospitalized patients with opioid use disorder: a retrospective chart review. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00723-w

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00723-w

Keywords: opioid use disorder, fentanyl, SIFI, opioid agonist treatment, hospitalized patients, withdrawal management, self-directed discharge, buprenorphine, slow-release oral morphine, Vancouver General Hospital, retrospective chart review, harm reduction